Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols

Craig R. Nichols, Elyse S. Breeden, Patrick Loehrer, Stephen D. Williams, Lawrence Einhorn

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Background: Case reports have suggested that treatment with high-dose etoposide can result in development of a unique secondary leukemia. Purpose: This study was designed to estimate the risk of developing leukemia for patients receiving conventional doses of etoposide along with cisplatin and bleornycin. Methods: We reviewed the records at Indiana University of all untreated patients entering clinical trials using etoposide at conventional doses (cumulative dose, 2000 mg/rn2 or less) for germ cell cancer between 1982 and 1991. The records of all patients who received a chemotherapy regimen containing etoposide, ifosfamide, or cisplatin after failing to respond to primary chemotherapy were also reviewed. Results: Between 1982 and 1991, 538 patients entered serial clinical trials with planned cumulative etoposide doses of 1500-2000 mg/rn2 in combination with cisplatin plus either ifosfamide or bleomycin. Of these 538 patients, 348 received an etoposide combination as initial chemotherapy and 190 received etoposide as part of salvage treatment. To date, 315 patients are alive, with median follow-up of 4.9 years, and 337 patients have had follow-up beyond 2 years. Two patients (0.37%) developed leukemia. One developed acute undifferentiated leukemia with a t(4;11) (q21;q23) cytogenetic abnormality 2.0 years after starting etoposide-based therapy, and one developed acute myelomonoblastic leukemia with no chromosome abnormalities 2.3 years after beginning chemotherapy. During this period, several hundred patients were treated with etoposide-based chemotherapy and did not enter clinical trials. Three of these patients are known to have developed hematologic abnormalities, including one patient with acute monoblastic leukemia with a t(11;19)(q13;p13) abnormality. Conclusions: Secondary leukemia after treatment with a conventional dose of etoposide does occur, but the low incidence does not alter the risk-to-benefit ratio of etoposide-based chemotherapy in germ cell cancer. Implications: The reports of leukemia associated with high doses of etoposide emphasize the need for diligent follow-up of patients and make careful risk-to- benefit analysis imperative. [J NatI Cancer Inst 85:36-40, 1993].

Original languageEnglish
Pages (from-to)36-40
Number of pages5
JournalJournal of the National Cancer Institute
Volume85
Issue number1
DOIs
StatePublished - Jan 6 1993

Fingerprint

Chemotherapy
Germ Cell and Embryonal Neoplasms
Leukemia
Etoposide
Tumors
Tumor
Dose
Cells
Cell
Cisplatin
Clinical Trials
Acute
Drug Therapy
Cancer
Salvaging
Ifosfamide
Chromosomes
Chromosome Aberrations
Review
Serials

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging
  • Oncology
  • Cancer Research

Cite this

Secondary leukemia associated with a conventional dose of etoposide : Review of serial germ cell tumor protocols. / Nichols, Craig R.; Breeden, Elyse S.; Loehrer, Patrick; Williams, Stephen D.; Einhorn, Lawrence.

In: Journal of the National Cancer Institute, Vol. 85, No. 1, 06.01.1993, p. 36-40.

Research output: Contribution to journalArticle

@article{fea41d80e44043e68c456e98b4d77613,
title = "Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols",
abstract = "Background: Case reports have suggested that treatment with high-dose etoposide can result in development of a unique secondary leukemia. Purpose: This study was designed to estimate the risk of developing leukemia for patients receiving conventional doses of etoposide along with cisplatin and bleornycin. Methods: We reviewed the records at Indiana University of all untreated patients entering clinical trials using etoposide at conventional doses (cumulative dose, 2000 mg/rn2 or less) for germ cell cancer between 1982 and 1991. The records of all patients who received a chemotherapy regimen containing etoposide, ifosfamide, or cisplatin after failing to respond to primary chemotherapy were also reviewed. Results: Between 1982 and 1991, 538 patients entered serial clinical trials with planned cumulative etoposide doses of 1500-2000 mg/rn2 in combination with cisplatin plus either ifosfamide or bleomycin. Of these 538 patients, 348 received an etoposide combination as initial chemotherapy and 190 received etoposide as part of salvage treatment. To date, 315 patients are alive, with median follow-up of 4.9 years, and 337 patients have had follow-up beyond 2 years. Two patients (0.37{\%}) developed leukemia. One developed acute undifferentiated leukemia with a t(4;11) (q21;q23) cytogenetic abnormality 2.0 years after starting etoposide-based therapy, and one developed acute myelomonoblastic leukemia with no chromosome abnormalities 2.3 years after beginning chemotherapy. During this period, several hundred patients were treated with etoposide-based chemotherapy and did not enter clinical trials. Three of these patients are known to have developed hematologic abnormalities, including one patient with acute monoblastic leukemia with a t(11;19)(q13;p13) abnormality. Conclusions: Secondary leukemia after treatment with a conventional dose of etoposide does occur, but the low incidence does not alter the risk-to-benefit ratio of etoposide-based chemotherapy in germ cell cancer. Implications: The reports of leukemia associated with high doses of etoposide emphasize the need for diligent follow-up of patients and make careful risk-to- benefit analysis imperative. [J NatI Cancer Inst 85:36-40, 1993].",
author = "Nichols, {Craig R.} and Breeden, {Elyse S.} and Patrick Loehrer and Williams, {Stephen D.} and Lawrence Einhorn",
year = "1993",
month = "1",
day = "6",
doi = "10.1093/jnci/85.1.36",
language = "English",
volume = "85",
pages = "36--40",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Secondary leukemia associated with a conventional dose of etoposide

T2 - Review of serial germ cell tumor protocols

AU - Nichols, Craig R.

AU - Breeden, Elyse S.

AU - Loehrer, Patrick

AU - Williams, Stephen D.

AU - Einhorn, Lawrence

PY - 1993/1/6

Y1 - 1993/1/6

N2 - Background: Case reports have suggested that treatment with high-dose etoposide can result in development of a unique secondary leukemia. Purpose: This study was designed to estimate the risk of developing leukemia for patients receiving conventional doses of etoposide along with cisplatin and bleornycin. Methods: We reviewed the records at Indiana University of all untreated patients entering clinical trials using etoposide at conventional doses (cumulative dose, 2000 mg/rn2 or less) for germ cell cancer between 1982 and 1991. The records of all patients who received a chemotherapy regimen containing etoposide, ifosfamide, or cisplatin after failing to respond to primary chemotherapy were also reviewed. Results: Between 1982 and 1991, 538 patients entered serial clinical trials with planned cumulative etoposide doses of 1500-2000 mg/rn2 in combination with cisplatin plus either ifosfamide or bleomycin. Of these 538 patients, 348 received an etoposide combination as initial chemotherapy and 190 received etoposide as part of salvage treatment. To date, 315 patients are alive, with median follow-up of 4.9 years, and 337 patients have had follow-up beyond 2 years. Two patients (0.37%) developed leukemia. One developed acute undifferentiated leukemia with a t(4;11) (q21;q23) cytogenetic abnormality 2.0 years after starting etoposide-based therapy, and one developed acute myelomonoblastic leukemia with no chromosome abnormalities 2.3 years after beginning chemotherapy. During this period, several hundred patients were treated with etoposide-based chemotherapy and did not enter clinical trials. Three of these patients are known to have developed hematologic abnormalities, including one patient with acute monoblastic leukemia with a t(11;19)(q13;p13) abnormality. Conclusions: Secondary leukemia after treatment with a conventional dose of etoposide does occur, but the low incidence does not alter the risk-to-benefit ratio of etoposide-based chemotherapy in germ cell cancer. Implications: The reports of leukemia associated with high doses of etoposide emphasize the need for diligent follow-up of patients and make careful risk-to- benefit analysis imperative. [J NatI Cancer Inst 85:36-40, 1993].

AB - Background: Case reports have suggested that treatment with high-dose etoposide can result in development of a unique secondary leukemia. Purpose: This study was designed to estimate the risk of developing leukemia for patients receiving conventional doses of etoposide along with cisplatin and bleornycin. Methods: We reviewed the records at Indiana University of all untreated patients entering clinical trials using etoposide at conventional doses (cumulative dose, 2000 mg/rn2 or less) for germ cell cancer between 1982 and 1991. The records of all patients who received a chemotherapy regimen containing etoposide, ifosfamide, or cisplatin after failing to respond to primary chemotherapy were also reviewed. Results: Between 1982 and 1991, 538 patients entered serial clinical trials with planned cumulative etoposide doses of 1500-2000 mg/rn2 in combination with cisplatin plus either ifosfamide or bleomycin. Of these 538 patients, 348 received an etoposide combination as initial chemotherapy and 190 received etoposide as part of salvage treatment. To date, 315 patients are alive, with median follow-up of 4.9 years, and 337 patients have had follow-up beyond 2 years. Two patients (0.37%) developed leukemia. One developed acute undifferentiated leukemia with a t(4;11) (q21;q23) cytogenetic abnormality 2.0 years after starting etoposide-based therapy, and one developed acute myelomonoblastic leukemia with no chromosome abnormalities 2.3 years after beginning chemotherapy. During this period, several hundred patients were treated with etoposide-based chemotherapy and did not enter clinical trials. Three of these patients are known to have developed hematologic abnormalities, including one patient with acute monoblastic leukemia with a t(11;19)(q13;p13) abnormality. Conclusions: Secondary leukemia after treatment with a conventional dose of etoposide does occur, but the low incidence does not alter the risk-to-benefit ratio of etoposide-based chemotherapy in germ cell cancer. Implications: The reports of leukemia associated with high doses of etoposide emphasize the need for diligent follow-up of patients and make careful risk-to- benefit analysis imperative. [J NatI Cancer Inst 85:36-40, 1993].

UR - http://www.scopus.com/inward/record.url?scp=0027475639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027475639&partnerID=8YFLogxK

U2 - 10.1093/jnci/85.1.36

DO - 10.1093/jnci/85.1.36

M3 - Article

C2 - 7677934

AN - SCOPUS:0027475639

VL - 85

SP - 36

EP - 40

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -